Dear Ocumetics Team, Partners and Stakeholders,
I am thrilled to share an exciting update in our journey to revolutionize vision correction technology. Last week, we proudly announced, in a separate press release, the commencement of manufacturing for the Ocumetics accommodating intraocular lens (IOL). This is not just a milestone for our corporation, but a significant leap forward in eye care.
Our collaboration with Bioana, a leader in medical device design and manufacturing, marks a pivotal moment in our mission. Bioana’s state-of-the-art facilities and unmatched expertise make them the ideal partner for bringing our innovative lenses to life. Their commitment to excellence mirrors our own, and together, we are poised to set new standards in vision enhancement.
The Ocumetics accommodating IOL is designed to provide excellent visual acuity across all distances, addressing both near and far vision with great clarity. Our journey towards this groundbreaking development has been driven by a clear company vision: to create a lens that not only meets but exceeds the expectations of patients and eye care professionals alike. The initial production run of these lenses is a crucial step as we prepare for the upcoming first-in-human clinical study in the Dominican Republic. This study will provide us with essential data on the safety and efficacy of our lenses, guiding us as we navigate the regulatory landscape to bring this product to market.
I want to extend my deepest appreciation to Adriana Torres, COO and Chief Engineer at Bioana, and her exceptional team. Their enthusiasm and dedication to this project have been instrumental in reaching this milestone. We are honored to have Bioana as our manufacturing partner, and I am confident that their expertise will ensure the highest standards of quality and precision in producing our lenses.
In closing, let us celebrate this remarkable achievement and look forward to the exciting opportunities that lie ahead. Together, we are redefining the future of eye care, and I am honored to be on this journey with all of you.
Thank you for your dedication and support.
Warm regards,
Dean Burns
President & CEO,
Ocumetics Technology Corp.
Ocumetics Director and CEO, Dean Burns, covers key details of our upcoming first-in-human study and recently opened private placement financing. Topics will include: Final steps leading up to the first-in-human study Details on the now-open private placement investment opportunity Live Q&A session with Dean Burns Thanks to everyone who joined us for the Webinar. It
Ocumetics Director and CEO, Dean Burns, walks us through relevant topics including: First-in-human study timing Remaining steps to first-in-human study Q&A session Thanks to everyone who joined us for the Webinar. It was an amazing turnout, and it was great to hear your questions and comments. We look forward to hosting more webinars in the
Today marks a defining moment in the history of Ocumetics—and in the future of vision restoration worldwide. It is with great pride and anticipation that I share we are now entering the final stages before our First-In-Human (FIH) clinical study for the Ocumetics Lens. This is more than a corporate milestone; it is the beginning
Ocumetics Director and CEO, Dean Burns, walks through relevant topics including:1. Development Update on the Ocumetics IOL2. Remaining steps to first-in-human study3. Q&A session Thanks to everyone who joined us for the Webinar. It was an amazing turnout, and it was great to hear your questions and comments. We look forward to hosting more webinars in
